FilingReader Intelligence
CStone's Gavreto approved for localized manufacturing in China
July 10, 2025 at 12:09 AM UTC•By FilingReader AI
CStone Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has approved the localized manufacturing application for GAVRETO® (pralsetinib, 100mg), marking a significant milestone for the company's lifecycle management strategy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2616•Hong Kong Exchange
News Alerts
Get instant email alerts when CStone Pharmaceuticals publishes news
Free account required • Unsubscribe anytime